{"id":"nimotuzumab-plus-paclitaxel","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Neutropenia"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"20-40%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL2108359","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Nimotuzumab binds to the EGFR, preventing it from interacting with its ligands and thereby inhibiting the receptor's downstream signaling pathways. Paclitaxel works by stabilizing microtubules, preventing cell division and ultimately leading to cell death.","oneSentence":"Nimotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while paclitaxel is a taxane that inhibits cell division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:23.704Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT07457528","phase":"PHASE2","title":"Efficacy and Safety of Neo-CRT Plus Serplulimab, Nimotuzumab in Patients With Locally Advanced Resectable ESCC","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-03-12","conditions":"Resectable Esophageal Squamous Cell Carcinoma","enrollment":46},{"nctId":"NCT07240766","phase":"PHASE2","title":"HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2026-02-15","conditions":"Borderline Resectable Pancreatic Adenocarcinoma","enrollment":40},{"nctId":"NCT07388095","phase":"NA","title":"Adebrelimab Neoadjuvant Treatment for Resectable ESCC","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2026-02-15","conditions":"ESCC","enrollment":22},{"nctId":"NCT04821778","phase":"PHASE3","title":"Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2002-01-01","conditions":"Esophagus Cancer, Esophagogastric Junction Cancer, Chemoradiation","enrollment":2000},{"nctId":"NCT04821843","phase":"PHASE3","title":"Neoadjuvant Treatment Modalities in Esophageal Cancer","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2002-01-01","conditions":"Esophageal Cancer, Chemotherapy Effect, Chemoradiation","enrollment":2000},{"nctId":"NCT07353723","phase":"PHASE2","title":"Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-11-15","conditions":"Head & Neck Cancer","enrollment":10},{"nctId":"NCT07310771","phase":"PHASE2","title":"Sintilimab-Nimotuzumab Induction Followed by Chemoradiation-Nimotuzumab in LA-HNSCC: Single-Arm Phase II","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-01-10","conditions":"Locally Advanced Head and Neck Squamous Cell Carcinoma (LA-SCCHN)","enrollment":23},{"nctId":"NCT07277452","phase":"PHASE2","title":"Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-10","conditions":"Pancreatic Cancer, Adult","enrollment":156},{"nctId":"NCT06770452","phase":"PHASE2","title":"HRS-4642 With Nimotuzumab and Chemotherapy for First-line Treatment of Advanced Pancreatic Cancer Patients","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2025-03-25","conditions":"Metastatic Pancreatic Carcinoma","enrollment":32},{"nctId":"NCT07105592","phase":"PHASE1, PHASE2","title":"A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Fudan University","startDate":"2025-05-13","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":68},{"nctId":"NCT04456322","phase":"PHASE3","title":"Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-08-17","conditions":"Nasopharyngeal Carcinoma","enrollment":381},{"nctId":"NCT06938503","phase":"PHASE2","title":"AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-04-21","conditions":"Pancreatic Cancer, Adult","enrollment":48},{"nctId":"NCT04223024","phase":"PHASE2","title":"Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2020-01-31","conditions":"Nasopharyngeal Carcinoma","enrollment":246},{"nctId":"NCT06781073","phase":"PHASE3","title":"Nimotuzumab in Combined With Chemotherapy for Treatment of IVB Stage,Rrecurrent or Persistent Cervical Carcinoma","status":"COMPLETED","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2017-07-06","conditions":"Cervical Squamous Cell Carcinoma, Persistent","enrollment":118},{"nctId":"NCT06722911","phase":"PHASE2","title":"Study of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer","status":"RECRUITING","sponsor":"Zhejiang Provincial People's Hospital","startDate":"2024-11-15","conditions":"Pancreatic Cancer Resectable","enrollment":57},{"nctId":"NCT06718205","phase":"PHASE2","title":"Nimotuzumab Combined With Sintilimab and Chemotherapy for Advanced Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Zhengzhou University","startDate":"2023-03-08","conditions":"Esophageal Cancer","enrollment":112},{"nctId":"NCT05978050","phase":"PHASE3","title":"Nimotuzumab Combined With Paclitaxel for Recurrent Metastatic Gastric or Esophagogastric Junction Adenocarcinoma","status":"RECRUITING","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2024-08-01","conditions":"Gastric or Esophagogastric Junction Adenocarcinoma","enrollment":354},{"nctId":"NCT06561763","phase":"PHASE3","title":"TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-08-20","conditions":"High Risk Locally Advanced Nasopharyngeal Carcinoma","enrollment":416},{"nctId":"NCT06404840","phase":"PHASE2","title":"Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study","status":"RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-05-06","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT06405685","phase":"PHASE2","title":"Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2023-04-27","conditions":"Pancreatic Cancer","enrollment":30},{"nctId":"NCT05351762","phase":"PHASE2","title":"Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2022-07-01","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":55},{"nctId":"NCT04475016","phase":"PHASE2","title":"TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2020-08-12","conditions":"Penile Cancer","enrollment":29},{"nctId":"NCT03413579","phase":"PHASE3","title":"Evaluate Efficacy of the Association Nimotuzumab(HR3) /Cisplatin-Vinorelbine on Patients With Cervical Carcinom","status":"COMPLETED","sponsor":"El Kendi Pharmaceuticals Manufacturing Company","startDate":"2015-11","conditions":"Cervical Cancer","enrollment":37},{"nctId":"NCT02272699","phase":"PHASE2, PHASE3","title":"Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma","status":"WITHDRAWN","sponsor":"Peking University","startDate":"2014-11","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT02409186","phase":"PHASE3","title":"A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2015-03","conditions":"Prosthesis Survival","enrollment":200},{"nctId":"NCT01393080","phase":"NA","title":"Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2011-03","conditions":"Non-small Cell Lung Cancer","enrollment":160},{"nctId":"NCT02611700","phase":"PHASE3","title":"Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2015-11","conditions":"Esophageal Squamous Cell Carcinomas","enrollment":504},{"nctId":"NCT02039791","phase":"PHASE2","title":"Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer","status":"UNKNOWN","sponsor":"Biotech Pharmaceutical Co., Ltd.","startDate":"2013-01","conditions":"Cervical Cancer","enrollment":20},{"nctId":"NCT02041819","phase":"PHASE2","title":"Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus","status":"WITHDRAWN","sponsor":"Zhejiang University","startDate":"2014-02","conditions":"Squamous Cell Carcinoma of Esophagus","enrollment":""},{"nctId":"NCT02034968","phase":"PHASE2","title":"Nimotuzumab Plus Nab-paclitaxel and Cisplatin in Treating Patients With Advanced Esophageal Carcinoma","status":"WITHDRAWN","sponsor":"Zhejiang University","startDate":"2014-02","conditions":"Stage IV Esophageal Squamous Cell Carcinoma","enrollment":""},{"nctId":"NCT01688700","phase":"PHASE2","title":"Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2012-09","conditions":"Esophageal Squamous Cell Carcinoma Resectable","enrollment":60},{"nctId":"NCT01336049","phase":"PHASE2","title":"Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer","status":"UNKNOWN","sponsor":"Peking University","startDate":"2011-03","conditions":"Esophageal Squamous Cell Cancer","enrollment":70}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Combined with chemotherapy"],"phase":"phase_3","status":"active","brandName":"nimotuzumab plus paclitaxel","genericName":"nimotuzumab plus paclitaxel","companyName":"Biotech Pharmaceutical Co., Ltd.","companyId":"biotech-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nimotuzumab is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), while paclitaxel is a taxane that inhibits cell division. Used for Non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}